Hamisi M Malebo1, Sarah D'Alessandro2,3, Yehenew A Ebstie4, Harouna Sorè5, Alain R Tenoh Guedoung4, Shaaban J Katani1, Silvia Parapini2,3, Donatella Taramelli3,6, Annette Habluetzel3,4. 1. Department of Traditional Medicine Research, National Institute for Medical Research, Dar es Salaam, Tanzania. 2. Dipartimento di Scienze Biomediche per la Salute , University of Milan, Milan, Italy. 3. Centro Interuniversitario di Ricerca Sulla Malaria/Italian Malaria Network, University of Milan, Milan, Italy. 4. School of Pharmacy, University of Camerino, Camerino, Italy. 5. Centre National de Recherche et de Formation sur le Paludisme (CNRFP), Ouagadougou, Burkina Faso. 6. Dipartimento di Scienze Farmacologiche e Biomolecolari, University of Milan, Milan, Italy.
Abstract
PURPOSE: Continuous efforts into the discovery and development of new antimalarials are required to face the emerging resistance of the parasite to available treatments. Thus, new effective drugs, ideally able to inhibit the Plasmodium life-cycle stages that cause the disease as well as those responsible for its transmission, are needed. Eight compounds from the Medicines for Malaria Venture (MMV) Malaria Box, potentially interfering with the parasite polyamine biosynthesis were selected and assessed in vitro for activity against malaria transmissible stages, namely mature gametocytes and early sporogonic stages. METHODS: Compound activity against asexual blood stages of chloroquine-sensitive 3D7 and chloroquine-resistant W2 strains of Plasmodium falciparum was tested measuring the parasite lactate dehydrogenase activity. The gametocytocidal effect was determined against the P. falciparum 3D7elo1-pfs16-CBG99 strain with a luminescent method. The murine P. berghei CTRP.GFP strain was employed to assess compounds activities against early sporogonic stage development in an in vitro assay simulating mosquito midgut conditions. RESULTS: Among the eight tested molecules, MMV000642, MMV000662 and MMV006429, containing a 1,2,3,4-tetrahydroisoquinoline-4-carboxamide chemical skeleton substituted at N-2, C-3 and C-4, displayed multi-stage activity. Activity against asexual blood stages of both strains was confirmed with values of IC50 (50% inhibitory concentration) in the range of 0.07-0.13 µM. They were also active against mature stage V gametocytes with IC50 values below 5 µM (range: 3.43-4.42 µM). These molecules exhibited moderate effects on early sporogonic stage development, displaying IC50 values between 20 and 40 µM. CONCLUSION: Given the multi-stage, transmission-blocking profiles of MMV000642, MMV000662, MMV006429, and their chemical characteristics, these compounds can be considered worthy for further optimisation toward a TCP5 or TCP6 target product profile proposed by MMV for transmission-blocking antimalarials.
PURPOSE: Continuous efforts into the discovery and development of new antimalarials are required to face the emerging resistance of the parasite to available treatments. Thus, new effective drugs, ideally able to inhibit the Plasmodium life-cycle stages that cause the disease as well as those responsible for its transmission, are needed. Eight compounds from the Medicines for Malaria Venture (MMV) Malaria Box, potentially interfering with the parasite polyamine biosynthesis were selected and assessed in vitro for activity against malaria transmissible stages, namely mature gametocytes and early sporogonic stages. METHODS: Compound activity against asexual blood stages of chloroquine-sensitive 3D7 and chloroquine-resistant W2 strains of Plasmodium falciparum was tested measuring the parasite lactate dehydrogenase activity. The gametocytocidal effect was determined against the P. falciparum 3D7elo1-pfs16-CBG99 strain with a luminescent method. The murine P. berghei CTRP.GFP strain was employed to assess compounds activities against early sporogonic stage development in an in vitro assay simulating mosquito midgut conditions. RESULTS: Among the eight tested molecules, MMV000642, MMV000662 and MMV006429, containing a 1,2,3,4-tetrahydroisoquinoline-4-carboxamide chemical skeleton substituted at N-2, C-3 and C-4, displayed multi-stage activity. Activity against asexual blood stages of both strains was confirmed with values of IC50 (50% inhibitory concentration) in the range of 0.07-0.13 µM. They were also active against mature stage V gametocytes with IC50 values below 5 µM (range: 3.43-4.42 µM). These molecules exhibited moderate effects on early sporogonic stage development, displaying IC50 values between 20 and 40 µM. CONCLUSION: Given the multi-stage, transmission-blocking profiles of MMV000642, MMV000662, MMV006429, and their chemical characteristics, these compounds can be considered worthy for further optimisation toward a TCP5 or TCP6 target product profile proposed by MMV for transmission-blocking antimalarials.
Authors: Darren J Creek; Hwa H Chua; Simon A Cobbold; Brunda Nijagal; James I MacRae; Benjamin K Dickerman; Paul R Gilson; Stuart A Ralph; Malcolm J McConville Journal: Antimicrob Agents Chemother Date: 2016-10-21 Impact factor: 5.191
Authors: David M Floyd; Philip Stein; Zheng Wang; Jian Liu; Steve Castro; Julie A Clark; Michele Connelly; Fangyi Zhu; Gloria Holbrook; Amy Matheny; Martina S Sigal; Jaeki Min; Rajkumar Dhinakaran; Senthil Krishnan; Sridevi Bashyum; Spencer Knapp; R Kiplin Guy Journal: J Med Chem Date: 2016-08-25 Impact factor: 7.446
Authors: André Lin Ouédraogo; Guido J H Bastiaens; Alfred B Tiono; Wamdaogo M Guelbéogo; Kevin C Kobylinski; Alphonse Ouédraogo; Aïssata Barry; Edith C Bougouma; Issa Nebie; Maurice San Ouattara; Kjerstin H W Lanke; Lawrence Fleckenstein; Robert W Sauerwein; Hannah C Slater; Thomas S Churcher; Sodiomon B Sirima; Chris Drakeley; Teun Bousema Journal: Clin Infect Dis Date: 2014-11-19 Impact factor: 9.079
Authors: Jeremy N Burrows; Stephan Duparc; Winston E Gutteridge; Rob Hooft van Huijsduijnen; Wiweka Kaszubska; Fiona Macintyre; Sébastien Mazzuri; Jörg J Möhrle; Timothy N C Wells Journal: Malar J Date: 2017-01-13 Impact factor: 2.979
Authors: Hamisi M Malebo; Tanja Wenzler; Monical Cal; Sauda M Swaleh; Maurice O Omolo; Ahmed Hassanali; Urs Séquin; Daniel Häussinger; Petur Dalsgaard; Matthias Hamburger; Reto Brun; Isaiah O Ndiege Journal: BMC Complement Altern Med Date: 2013-02-27 Impact factor: 3.659
Authors: Robyn S Kent; Emma M Briggs; Beatrice L Colon; Catalina Alvarez; Sara Silva Pereira; Mariana De Niz Journal: Front Cell Infect Microbiol Date: 2022-06-06 Impact factor: 6.073